Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : US Department of Defense
Deal Size : $74.0 million
Deal Type : Agreement
Details : Under the agreement, Evotec Biologics will develop drug product prototypes of new monoclonal antibodies (mAbs) using AI-driven de novo antibody design through the execution of Phase I first-in human clinical trials.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
May 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : US Department of Defense
Deal Size : $74.0 million
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $6.6 million
Deal Type : Funding
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
Details : The funding will support TB drug discovery, and will allow the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 24, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $6.6 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Open Philanthropy
Deal Size : $1.7 million
Deal Type : Funding
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
Details : The funding will support the discovery and development of RNA-targeting small molecules by leveraging its rSM platform for potential first-in-class therapeutics against Henipaviruses.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Open Philanthropy
Deal Size : $1.7 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Evotec Biologics Receives Grant to Enable an Antibody Product for the Prevention of COVID-19
Details : Evotec Biologics will use its proprietary software toolset Abacus™ to perform an in silico analysis of several lead candidate sequences of potent anti-SARS-CoV-2 mAbs provided to the foundation by several leading academic medical centres around the wor...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 19, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Sun Yat-sen University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 28, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Sun Yat-sen University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NI007
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Neurimmune
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.
Product Name : NI007
Product Type : Antibody
Upfront Cash : Undisclosed
January 04, 2020
Lead Product(s) : NI007
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Neurimmune
Deal Size : Undisclosed
Deal Type : Collaboration